New cancer drug combo enters first human tests
NCT ID NCT06031441
First seen Jun 24, 2026 · Last updated Jun 30, 2026 · Updated 3 times
Summary
This early-stage trial is testing an experimental drug called RO7566802, alone or with the immunotherapy atezolizumab, in people with advanced solid tumors that have not responded to standard treatments. The study aims to find a safe dose and check for early signs of activity. About 250 participants will take part in this first-in-human study.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
RO7566802 (an experimental drug) and atezolizumab (Tecentriq, an immunotherapy)
What this could lead to
If it works, this could point toward a new treatment option for people with advanced solid tumors that have stopped responding to standard therapies.
What could go wrong
This is a very early (Phase 1) trial, so the main goal is safety, not effectiveness. The drug may not work or could have serious side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Addenbrooke's Hospital
RECRUITINGCambridge, CB2 0QQ, United Kingdom
-
British Columbia Cancer Agency - 600 10th Ave W
RECRUITINGVancouver, British Columbia, V5Z 4E6, Canada
-
Churchill Hospital
RECRUITINGOxford, OX3 7LJ, United Kingdom
-
Icahn School of Medicine at Mount Sinai (ISMMS)
RECRUITINGNew York, New York, 10029, United States
-
Leicester Royal Infirmary
RECRUITINGLeicester, LE1 5WW, United Kingdom
-
Magee-Woman's Hospital
RECRUITINGHarrisburg, Pennsylvania, 17109, United States
-
National Cancer Centre
RECRUITINGSingapore, 168583, Singapore
-
National University Hospital
RECRUITINGSingapore, 119074, Singapore
-
Peter Maccallum Cancer Centre
RECRUITINGMelbourne, Victoria, 3000, Australia
-
Princess Margaret Cancer Centre
RECRUITINGToronto, Ontario, M5G 1Z5, Canada
-
SCRI Oncology Partners
RECRUITINGNashville, Tennessee, 37203, United States
-
Sarah Cannon Research Institute
RECRUITINGLondon, W1G 6AD, United Kingdom
-
St Bartholomew's Hospital
RECRUITINGLondon, EC1A 7BE, United Kingdom
-
St Vincent's Hospital Sydney
RECRUITINGDarlinghurst, New South Wales, 2010, Australia
-
The Ohio State University
RECRUITINGColumbus, Ohio, 43221-3502, United States
-
The Royal Marsden hospital
RECRUITINGSutton, SM2 5PT, United Kingdom
-
University of Alabama at Birmingham (UAB)
RECRUITINGBirmingham, Alabama, 35233, United States
-
Yale Cancer Center
RECRUITINGNew Haven, Connecticut, 06520, United States